Sponsors (2)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Requires the Department of Health and Human Services to maintain an updated Essential Medicines List and to assess, map, and analyze supply chains for those drugs to find vulnerabilities that could cause shortages or pose national security risks. It directs HHS to share specified facility and production data with other federal agencies, use data analytics for predictive modeling, protect sensitive information, and report findings to Congress on set timelines.
The bill increases visibility into critical drug and API supply chains and strengthens preparedness and domestic manufacturing incentives—potentially reducing shortages for patients and hospitals—but does so at the cost of new government spending, industry reporting burdens, market disruptions, and heightened data‑sharing/privacy risks.
Hospitals and patients (especially those with chronic conditions) gain earlier detection and reduced risk of gaps in essential medicines because a national essential medicines list, mapped supply chains, and predictive analytics enable targeted actions to secure supplies.
Federal, state, and local governments strengthen preparedness for chemical, biological, radiological, or nuclear (CBRN) incidents and other public‑health emergencies because the list and supply‑chain analysis identify critical drugs/APIs and support use of tools (e.g., DPA) to boost domestic production.
Policymakers, Congress, and suppliers gain greater transparency and accountability through published lists, required reporting, and regular updates, improving coordination and oversight of mitigation efforts and making progress visible to the public and lawmakers.
Taxpayers and public budgets could face significant new costs because stockpiling, using authorities (like the DPA), incentives for domestic manufacturing, and building analytics/mapping capabilities may require federal spending or subsidies.
Manufacturers and small suppliers will face increased reporting and compliance burdens (location, production, supplier data) and may be reluctant to share proprietary information, raising costs and possibly limiting industry cooperation.
If the list, assessments, or mapping efforts are delayed, incomplete, or not followed by concrete procurement and mitigation actions, patients and hospitals may get a false sense of security without actual reductions in shortages.
Introduced June 26, 2025 by Doris Matsui · Last progress June 26, 2025